Ultime notizie per SoundHound AI (NASDAQ:SOUN) Azioni

SOUNDHOUND AI INC-A

SoundHound AI

SoundHound AI Inc is an innovator of conversational intelligence, offering an independent Voice AI platform that enables businesses across industries to deliver high-quality conversational experiences to customers. The company's voice AI delivers speed and accuracy in numerous languages to product creators and service providers across retail, financial services, healthcare, automotive, smart devices, and restaurants via groundbreaking AI-driven products like Smart Answering, Smart Ordering, Dynamic Drive-Thru, and Amelia AI Agents.

10 Stocks Jim Cramer Says Will Thrive Despite Trump’s Tariffs

News

Markets

Media

Trading Ideas

PLTR

RDFN

SHOP

SOUN

Un&#39;analisi approfondita delle raccomandazioni del conduttore di &#39;Mad Money&#39; e delle possibili opportunità offerte dal mercato finanziario.

Jim Cramer: ecco i titoli da comprare e vendere - L&#39;analisi completa

jim cramer chart shutter

SERV

L&#39;esperto indica i titoli da acquistare e da evitare. Focus su dividendi, crescita e strategie di investimento a lungo termine.

Da Accenture a LPX: i consigli dell&#39;esperto Jim Cramer a &#34;Mad Money&#34;

What Happened

Equities

Market Summary

Broad U.S. Equity ETFs

ETFs

AMZN

NVDA

RIVN

SOFI

Il sogno è finito per le azioni nate sui social media? Analizziamo cause e conseguenze del tonfo e cosa devono aspettarsi gli investitori.

Meme stock al collasso: GameStop, Palantir e le altre &#34;stelle&#34; dei social media affondano

SoundHound AI, Inc. - Class A Common Stock

SoundHound AI Inc

SOUND GLOBAL LTD ORD by Sound Global Ltd.

Sound Energy PLC

Sound Enhanced Fixed Income ETF

Sound Equity Dividend Income ETF

Sound Financial Bancorp, Inc. - Common Stock

Sound Financial Bancorp Inc

Sound Group Inc. - American Depositary Shares

Sound Group Inc

Sound Point Meridian Capital, Inc. 8.00% Series A Preferred Shares Due 2029

Sound Point Meridian Capital, Inc. Common Stock

SoundThinking Inc

SOUNDWILL HLDGS LTD NEW by Soundwill Holdings Ltd.

Soundwill Holdings Ltd

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a<a href="https://www.benzinga.com/yield-investments"> high dividend payout</a>.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock Ratings</a> page. Traders can sort through Benzinga's extensive database of analyst ratings, including <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">by analyst accuracy</a>.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the energy sector.
<h3 class="wp-block-heading">Kimbell Royalty Partners, LP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KRP#NYSE">KRP</a>)</h3>
<ul>
<li>Dividend Yield: 11.18%</li>
<li>Truist Securities analyst Neal Dingmann downgraded the stock from Buy to Hold and cut the price target from $22 to $16 on March 4, 2025. This analyst has an accuracy rate of 65%.</li>
<li>Raymond James analyst John Freeman maintained a Strong Buy rating and raised the price target from $19 to $23 on Jan. 23, 2025. This analyst has an accuracy rate of 79%.</li>
<li>Recent News: Kimbell Royalty Partners will release its first quarter financial results on Thursday, May 8, before the market open.</li>
<li>Benzinga Pro&#8217;s real-time newsfeed alerted to latest <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0403">KRP news</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0403"><img loading="lazy" decoding="async" width="903" height="837" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/03045124/image-32.png" alt="" class="wp-image-854845" style="width:535px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/03045124/image-32.png 903w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/03045124/image-32-300x278.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/03045124/image-32-768x712.png 768w" sizes="(max-width: 903px) 100vw, 903px" /></a></figure>
<h3 class="wp-block-heading">Delek Logistics Partners, LP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DKL#NYSE">DKL</a>)</h3>
<ul>
<li>Dividend Yield: 10.13%</li>
<li>Raymond James analyst Justin Jenkins maintained an Outperform rating and raised the price target from $44 to $46 on Jan. 28, 2025. This analyst has an accuracy rate of 78%.</li>
<li>Truist Securities analyst Neal Dingmann maintained a Buy rating and boosted the price target from $46 to $50 on Nov. 18, 2024. This analyst has an accuracy rate of 65%.</li>
<li>Recent News: On Feb. 25, Delek Logistics Partners posted better-than-expected quarterly earnings.</li>
<li>Benzinga Pro's real-time newsfeed alerted to latest DKL <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0403">news </a></li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0403"><img loading="lazy" decoding="async" width="903" height="847" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/03045153/image-1-8.png" alt="" class="wp-image-854846" style="width:652px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/03045153/image-1-8.png 903w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/03045153/image-1-8-300x281.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/03045153/image-1-8-768x720.png 768w" sizes="(max-width: 903px) 100vw, 903px" /></a></figure>
<h3 class="wp-block-heading">Western Midstream Partners, LP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WES#NYSE">WES</a>)</h3>
<ul>
<li>Dividend Yield: 8.41%</li>
<li>UBS analyst Shneur Gershuni maintained a Neutral rating and lowered the price target from $40 to $37 on Nov. 15, 2024. This analyst has an accuracy rate of 82%.</li>
<li>Morgan Stanley analyst Robert Kad downgraded the stock from Equal-Weight to Underweight and cut the price target from $42 to $40 on Oct. 25, 2024. This analyst has an accuracy rate of 78%.</li>
<li>Recent News: On Feb. 26, Western Midstream posted weak quarterly earnings.</li>
<li>Benzinga Pro&#8217;s real-time newsfeed alerted to <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0403">latest WES news</a> </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0403"><img loading="lazy" decoding="async" width="910" height="840" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/03045227/image-33.png" alt="" class="wp-image-854849" style="width:435px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/03045227/image-33.png 910w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/03045227/image-33-300x277.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/04/03045227/image-33-768x709.png 768w" sizes="(max-width: 910px) 100vw, 910px" /></a></figure>
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/04/44622367/acuity-rh-and-3-stocks-to-watch-heading-into-thursday">Acuity, RH And 3 Stocks To Watch Heading Into Thursday</a> </li>
</ul>
Photo via Shutterstock

Dividends

Price Target

Pre-Market Outlook

Analyst Ratings

Wall Street's Most Accurate Analysts Weigh In On 3 Energy Stocks With Over 8% Dividend Yields

Jefferies analyst Sean Milligan maintains Enphase Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENPH#NASDAQ">ENPH</a>) with a Underperform and lowers the price target from $54 to $44.

ENPH

Jefferies Maintains Underperform on Enphase Energy, Lowers Price Target to $44

B of A Securities analyst Craig Siegenthaler maintains Franklin Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BEN#NYSE">BEN</a>) with a Underperform and lowers the price target from $20 to $17.

B of A Securities Maintains Underperform on Franklin Resources, Lowers Price Target to $17

As trade tensions heat up, one sector might have the immunity investors need &#8211; biopharma. JPMorgan analyst Chris Schott sees the industry as a relative &#8220;safe haven&#8221; despite looming <a href="https://www.benzinga.com/topic/tariffs">pharmaceutical-specific tariffs</a>, thanks to its high-margin business model and operational flexibility.
Read Also: <a href="https://www.benzinga.com/markets/equities/25/04/44620686/sp-500-nasdaq-futures-plunge-over-3-as-trumps-reciprocal-tariff-plan-hits-market-confidence">Trump&#8217;s &#8216;Reciprocal Tariff&#8217; Plan Hits Market Confidence As Dow Futures Drops Over 830 Points</a>
<h2 class="wp-block-heading">Tariffs Loom, But Biopharma Stands Strong</h2>
While the White House has not revealed details on pharma-related tariffs, broader trade restrictions announced today have put investors on edge. Schott acknowledges that some uncertainty will linger until the Section 232 pharmaceutical-specific tariffs are fully outlined in the coming weeks. However, he believes the sector has the tools to weather any potential impact.
Biopharma companies benefit from low capital expenditure intensity and high gross margins, making them more resilient in adjusting to cost pressures. Many also can shift intellectual property and manufacturing to the U.S. if needed while finding cost efficiencies elsewhere.
<h2 class="wp-block-heading">When Will The Impact Be Felt?</h2>
For now, companies appear to have time on their side. Schott anticipates that any direct financial impact from tariffs will likely hit in 2026 rather than 2025, as firms work through existing inventory already in the U.S. That gives the sector a buffer period to assess the extent of the tariffs and adapt accordingly.
<h2 class="wp-block-heading">Actionable ETFs For Investors</h2>
Investors looking to capitalize on biopharma&#8217;s defensive positioning amid tariff uncertainty may consider iShares U.S. Pharmaceuticals ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IHE#NYSE">IHE</a>) and SPDR S&amp;P Pharmaceuticals ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPH#NYSE">XPH</a>). These funds provide exposure to leading drugmakers who are expected to navigate potential trade disruptions more smoothly than other industries.
<h2 class="wp-block-heading">Key Questions Still Remain</h2>
Several unknowns still need to be addressed: What will the tariff levels be by country? Will they target low-cost active pharmaceutical ingredients (APIs) or final drug products with higher cost implications? Will these tariffs remain in place in the long term?
Schott expects companies to shed more light on these issues in their upcoming earnings calls. 
Until then, while tariffs shake the broader market, biopharma appears to have taken its medicine &#8211; staying strong while others scramble.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/25/04/44622346/trumps-reciprocal-tariff-math-a-masterclass-in-economic-absurdity">Trump&#8217;s &#8216;Reciprocal Tariff&#8217; Math: A Masterclass In Economic Absurdity</a></li>
</ul>
Photo: Shutterstock

Analyst Color

Biotech

Health Care

General

iShares Dow Jones US Pharmaceuticals Index Fund

Biopharma: A 'Safe Haven' As Tariff Turmoil Rages On?

U.S. stock futures were lower this morning, with the Dow futures falling more than 1,000 points on Thursday.
Shares of RH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RH#NYSE">RH</a>) fell sharply in today's pre-market trading after the company reported weaker-than-<a href="https://in.benzinga.com/news/earnings/25/04/44616824/rh-q4-earnings-shares-sink-as-revenue-eps-miss-expectations">expected fourth-quarter financial results.</a>
RH reported fourth-quarter revenue of $812.41 million, missing the consensus estimate of $829.56 million, according to Benzinga Pro. The luxury retailer reported fourth-quarter adjusted earnings of $1.58 per share, missing analyst estimates of $1.92 per share.
RH shares dipped 26.6% to $182.97 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul>
<li>AdvanSix Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASIX#NYSE">ASIX</a>) dipped 29% to $16.00 in pre-market trading.</li>
<li>Hamilton Beach Brands Holding Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HBB#NYSE">HBB</a>) fell 24.7% to $15.01 in pre-market trading.</li>
<li>Waton Financial Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WTF#NASDAQ">WTF</a>) shares dipped 20.3% to $5.60 in pre-market trading following a 65% decline on Wednesday. Waton Financial announced the closing of initial public offering with simultaneous full exercise of the over-allotment option.</li>
<li>RxSight, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXST#NASDAQ">RXST</a>) shares fell 19.2% to $21.00 in pre-market trading after the company announced preliminary first quarter revenue and revised 2025 guidance.</li>
<li>Franklin Covey Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FC#NYSE">FC</a>) shares tumbled 14.4% to $23.87 in pre-market trading following weak quarterly sales.</li>
<li>lululemon athletica inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LULU#NASDAQ">LULU</a>) fell 13% to $246.00 in pre-market trading.</li>
<li>The Gap, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GAP#NYSE">GAP</a>) fell 12.6% to $19.57 in pre-market trading.</li>
<li>NIKE, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NKE#NYSE">NKE</a>) dipped 11.6% to $57.44 in pre-market trading.</li>
<li>Thryv Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THRY#NASDAQ">THRY</a>) dipped 10.1% to $11.79 in pre-market trading.</li>
<li>BrightView Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BV#NYSE">BV</a>) dipped 8.3% to $12.23 in pre-market trading.</li>
<li>Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) fell 7.4% to $207.25 in pre-market trading. Tigress Financial analyst Ivan Feinseth maintained Apple with a Strong Buy and raised the price target from $295 to $300.</li>
<li>CNB Financial Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCNE#NASDAQ">CCNE</a>) fell 6.8% to $20.97 in pre-market trading.</li>
<li>Tesla, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) fell 5.7% to $266.66 in pre-market trading after gaining over 5% on Wednesday.</li>
<li>NVIDIA Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) dipped 5.3% to $104.56 in pre-market trading.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/04/44622367/acuity-rh-and-3-stocks-to-watch-heading-into-thursday">Acuity, RH And 3 Stocks To Watch Heading Into Thursday</a></li>
</ul>
Photo via Shutterstock

Movers

AAPL

ASIX

CCNE

LULU

RXST

THRY

TSLA

RH Posts Downbeat Earnings, Joins Apple, Tesla, Nvidia And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

B of A Securities analyst Craig Siegenthaler maintains Affiliated Managers Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMG#NYSE">AMG</a>) with a Neutral and lowers the price target from $211 to $195.

B of A Securities Maintains Neutral on Affiliated Managers Group, Lowers Price Target to $195

Canaccord Genuity analyst Michael Graham maintains Sportradar Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRAD#NASDAQ">SRAD</a>) with a Buy and raises the price target from $30 to $32.

SRAD

Canaccord Genuity Maintains Buy on Sportradar Gr, Raises Price Target to $32

B of A Securities analyst Craig Siegenthaler downgrades AllianceBernstein Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AB#NYSE">AB</a>) from Buy to Neutral and lowers the price target from $42 to $38.

Downgrades

B of A Securities Downgrades AllianceBernstein Holding to Neutral, Lowers Price Target to $38

Canaccord Genuity analyst Michael Walkley maintains BlackBerry (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BB#NYSE">BB</a>) with a Hold and lowers the price target from $4.75 to $4.25.

Canaccord Genuity Maintains Hold on BlackBerry, Lowers Price Target to $4.25

B of A Securities analyst Craig Siegenthaler upgrades Janus Henderson Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JHG#NYSE">JHG</a>) from Neutral to Buy and lowers the price target from $57 to $43.

Upgrades

Janus Henderson Group plc Ordinary Shares

B of A Securities Upgrades Janus Henderson Group to Buy, Lowers Price Target to $43

Macro Economic Events

Econ #s

Economics

U.S Vice President Vance Says: Musk Will Continue To Be An Adviser -Fox Interview

Baird analyst Andrew Wittmann maintains UniFirst (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNF#NYSE">UNF</a>) with a Neutral and lowers the price target from $218 to $197.

Baird Maintains Neutral on UniFirst, Lowers Price Target to $197

Fort Lauderdale, FL, April 03, 2025 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=V-0nYzFaL2nHiXE8MQvul89eQUpKHI9mbKvadvKCrHeI2_s5h3R-RL4gPhAxDulc0wsznXaWrBuUjiN3QO0nDT6_i9uEokQLL5Vm6VDJIkA=">MARA Holdings, Inc.</a> (NASDAQ: <a href="https://www.globenewswire.com/Tracker?data=hgFvAausj0i1ZfS9Vgw1tw_AYTQ5E6eBzO7be50lW9S1iouX4Mod6HQjZluQpJyctURoTeOcW39mQ0ZH1oR07A==">MARA</a>) ("MARA" or the "Company"), a global leader in leveraging digital asset compute to support energy transformation, today published unaudited bitcoin ("bitcoin" or "BTC") production updates for March 2025.
Management Commentary "In March, our production saw a 17% month-over-month increase in blocks won, even as global hashrate and mining difficulty grew," said Fred Thiel, MARA's chairman and CEO. "Our bitcoin holdings surpassed 47,000 BTC during March and the 242 blocks mined were the third most in a month on record.
"MARAPool is the only self-owned and operated mining pool among public miners, offering distinctive control and efficiency. Operating our own pool means no fees to external operators, higher earnings and superior performance. MARA Pool's luck factor has exceeded the network average by over 10% since launch, meaning more blocks mined and higher rewards.
"Energized hashrate grew 1% over February and we expect to finish construction of our 40-megawatt data center in Ohio by the end of April. We will continue to focus on being the dominant player in bitcoin mining while expanding our footprint in energy generation."

MARA

MARA Announces Bitcoin Production And Mining Operation Updates For March 2025; Company Won 242 Blocks, A 17% Increase MoM. Increased Bitcoin Holdings To 47,531 BTC

Baird analyst Andrew Wittmann maintains Fluor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLR#NYSE">FLR</a>) with a Neutral and lowers the price target from $46 to $43.

Baird Maintains Neutral on Fluor, Lowers Price Target to $43

NRXP

NRX Pharmaceuticals' HOPE Therapeutics Signs Term Sheet With A Global Medical Device Manufacturer; The Term Sheet Contemplates An Investment Of $2.5M To Purchase Series A Convertible Preferred Stock At $50M Pre-Money Valuation

CASI Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CASI#NASDAQ">CASI</a>, ", CASI", ))), a Cayman incorporated biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, announced that its special committee of the board of directors (the "Special Committee") has received an updated preliminary non-binding proposal letter (the "Proposal Letter"), dated April 2, 2025, from Dr. Wei-Wu He, Chairman of the board of directors and CEO of the Company, to acquire the entire business operations of the Company in China and all license-in, distribution and related rights in Asia (excluding Japan) related to certain pipeline products of the Company, including BI-1206, CID-103 and Thiotepa, for an aggregate purchase price of $20.0 million, which shall include assumption of approximately $20.0 million of indebtedness of the Company (the "Proposed Transaction").
The Proposal Letter updates the preliminary non-binding proposal letter submitted by Dr. He to the Company on June 21, 2024. The Proposal Letter conveys Dr. He's intent to make certain adjustment to the scope of, and considerations for, the pipeline products involved in the Proposed Transaction based on latest information disclosed by the Company.
As previously announced, the board of directors of the Company had formed the Special Committee to evaluate the Proposed Transaction, or any alternative strategic option that the Company may pursue. The Special Committee will continue to evaluate the Proposed Transaction in light of the latest development.

CASI

CASI Pharmaceuticals Receives Updated $20M Proposal From CEO Dr. Wei-Wu He To Acquire Co's Business Operations In China And Asian Rights To Certain Pipeline Products, With Special Committee Continuing Evaluation Of The Proposed Transaction And Strategic Alternatives

Baird analyst Peter Benedict maintains RH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RH#NYSE">RH</a>) with a Neutral and lowers the price target from $400 to $215.

Baird Maintains Neutral on RH, Lowers Price Target to $215

The AI revolution isn&#8217;t just about chips—it&#8217;s about the high-speed highways that move data between them. According to JPMorgan analyst Harlan Sur, Broadcom Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>) and Marvell Technology Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVL#NASDAQ">MRVL</a>) are at the center of this networking build-out, making them prime beneficiaries of <a href="https://www.benzinga.com/topic/artificial-intelligence">the AI boom</a>.
<h2 class="wp-block-heading">Networking Demand Surges with AI Compute</h2>
Sur highlights that the rapid expansion of accelerated computing &#8211; powered by Nvidia Corp&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) Blackwell GPUs, Alphabet Inc&#8216;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) Google&#8217;s TPUv6, and Amazon.com Inc's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) Trainium 2 &#8211; is fueling an insatiable need for faster networking. As hyperscalers scale out their data centers, demand for 800G and next-gen 1.6T networking solutions is set to soar through 2025 and beyond.
At the OFC Networking Conference this week, Broadcom showcased its dominance in high-performance switching, with its Tomahawk 5 and Jericho 3 chipsets seeing strong demand. The company is also gearing up for the launch of its 3nm Tomahawk 6 later this year, further strengthening its AI networking footprint.
Read Also: <a href="https://www.benzinga.com/trading-ideas/technicals/25/04/44588724/intel-make-or-break-moment-can-new-ceo-lip-bu-tan-turn-it-around">Intel Faces Make-Or-Break Moment: Can New CEO Lip-Bu Tan Turn It Around?</a>
<h2 class="wp-block-heading">Marvell: The King Of PAM4 DSPs</h2>
Marvell continues to dominate the PAM4 DSP market, commanding over 70% market share and generating more than $1.5 billion in revenue from this segment in 2024. 
The company is leading the charge in next-gen 1.6T AEC and silicon photonics (SiPho) solutions, positioning itself to capitalize on both scale-out and scale-up networking demand. With strong AI-ASIC ramps in the pipeline, Marvell's data center business looks set for solid Q/Q growth through the rest of the year, the analyst said.
<h2 class="wp-block-heading">Broadcom: The Networking Powerhouse</h2>
Broadcom, meanwhile, is flexing its dominance in high-performance networking. Its Tomahawk 5 switch (51.2Tbps throughput) is already in high-volume production, and the next-gen Tomahawk 6 (102Tbps) is expected to drop later this year. AI-related networking revenue is up over 60%, and Broadcom's deep lineup of scale-out and scale-up solutions—ranging from PCIe Gen5 connectivity to co-packaged optics—keeps it ahead of the pack, according to Sur.
<h2 class="wp-block-heading">Actionable ETFs for Investors</h2>
For those looking to gain exposure to this AI-driven networking surge, iShares Semiconductor ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SOXX#NASDAQ">SOXX</a>) and VanEck Semiconductor ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMH#NASDAQ">SMH</a>) both hold significant positions in Broadcom and Marvell, making them prime ways to ride this wave.
With hyperscalers racing to upgrade their AI infrastructure, Broadcom and Marvell are sitting in the sweet spot. 
With demand for ultra-high-speed networking solutions on the rise, these two semiconductor leaders appear well-positioned for further growth.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/03/44539735/nvidia-stock-an-attractive-opportunity-analyst-says-valuation-cheap-despite-china-restrictions">Nvidia Stock &#8216;An Attractive Opportunity,&#8217; Analyst Says Valuation Cheap Despite China Restrictions</a></li>
</ul>
Photo: asharkyu/Shutterstock.com

Long Ideas

Tech

AVGO

GOOG

GOOGL

MRVL

iShares PHLX SOX Semiconductor Sector Index Fund

SOXX

JPMorgan Says Broadcom, Marvell Could Dominate AI's Next Frontier — Here's Why

<a href="https://www.globenewswire.com/Tracker?data=7l57jPT7AZDn06CKZpFEvCZWIfVofhoCdY1ADg0wIzox9VuZpgQRe1PjoOSmOEVcGBL6lOiOros8Dh9aXF-XJoIVl6t6ZeONjLprU1SgmlU=">Akebia Therapeutics&#xAE;, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKBA#NASDAQ">AKBA</a>), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the European Commission (EC) to approve XOANACYL&#xAE; (Ferric Citrate as Coordination Complex) for the treatment of concomitant elevated serum phosphorous and iron deficiency in adult patients with chronic kidney disease (CKD).
Averoa, a renal-focused biopharmaceutical company, licensed the rights to develop and commercialize ferric citrate from Akebia in the European Economic Area and certain countries in Europe and the Middle East. Averoa recently announced the positive opinion from CHMP here: <a href="https://www.globenewswire.com/Tracker?data=YC3k_S4HYmByvgOHZ8KXr9C0l6cq2mm2kfWvZCIPt6Z_Lb_YAZuD_AN4OU8B8GfuKWmJWYc1ze_64nltBee9vEAkzlG0WPcS8tWwIQOgbg6vFL0aZwl9rFqnbqLk1eJ21wf7V3RWjz3kl4lrcqqsJ0FtpBJzHBRGq2fXfRng6WWEcZJcsByl-xY1MSoTfuiY4IfFo9KwQezWnnOVW2ZRKUgDbA9JFoMZh9bfpbTLWnRCZsioMOIoCuyDeRr2FdWMyD4-vYX-cKnW8l08ViedE5-LMOEdXv0Fd-LS6zelN-AJTu2nE1ZtTq8h_35h_TKX">https://averoa-pharma.org/wp-content/uploads/2025/04/20250402-AVA1014-Positive-opinion-EN-VF-2.04.2025.pdf</a>.
"We congratulate our partner Averoa on a positive step toward securing EMA approval for XOANACYL, and we will continue to support their efforts to deliver a treatment for complications of kidney disease to patients in Europe," said John P. Butler, Chief Executive Officer of Akebia.
The EC will review the CHMP recommendation, and a final decision is expected in approximately two months.

AKBA

Akebia Therapeutics Announces Committee For Medicinal Products For Human Use Of The European Medicines Agency Has Adopted A Positive Opinion Recommending The European Commission To Approve Xoanacyl For Treatment Of Concomitant Elevated Serum Phosphorous And Iron Deficiency In Adult Patients With Chronic Kidney Disease

Auralink AI processed $1.2M in billed switching activity in March 2025 (based on internal system data)
CallAI&#x2122; integration expected to enhance efficiency through AI-based call automation and routing
Infrastructure scaling and AI talent expansion underway to support platform growth
NEW YORK, NY / <a href="https://www.accessnewswire.com/">ACCESS Newswire</a> / April 3, 2025 / Nixxy, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NIXX#NASDAQ">NIXX</a>), or Nixxy, or the Company, today announced preliminary operational metrics for its Auralink AI subsidiary, highlighting internal system activity and progress toward broader platform readiness. In March 2025, Auralink AI processed approximately $1.2M in switching and billing activity, based on internal usage data and system modeling. Final revenue recognition will be determined in accordance with applicable accounting standards. Based on the higher-than-expected revenue, Nixxy will be reviewing April forecasts and revising them accordingly in the near future.

NIXX

Nixxy Issues Operational Milestone Update And Highlights AI Integration Progress; Auralink AI Processed $1.2M In Billed Switching Activity In March 2025

Press Releases

Securities Fraud Investigation Into SoundHound AI, Inc. (SOUN) Announced – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm

SOUN Investors Have Opportunity to Lead SoundHound AI, Inc.  Securities Fraud Lawsuit with the Schall Law Firm

Legal

ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of SoundHound AI

Law Offices of Howard G. Smith Encourages SoundHound AI, Inc. (SOUN) Investors To Inquire About Securities Fraud Class Action

Law Offices of Frank R. Cruz Encourages SoundHound AI, Inc. (SOUN) Investors To Inquire About Securities Fraud Class Action

SOUN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that SoundHound AI, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

SOUN Class Action Alert: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the SoundHound AI, Inc. Class Action

Comments

SoundHound AI

Notizie

Ultime notizie per SoundHound AI (NASDAQ:SOUN) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO